Objectives This study aimed to evaluate the therapeutic efficacy of telitacicept based on the conventional treatment in adults with idiopathic inflammatory myopathy (IIM), focusing on its impact on clinical manifestations. Methods IIM patients who had been treated with telitacicept for at least 3 months based on the conventional treatment from January 2023 to January 2024 were included in this study. The clinical response to telitacicept was determined based on the ACR/EULAR criteria for minimal, moderate, and major improvement in the total improvement score (TIS). Disease activity was monitored using Core Set Measures (CSMs), while myositis damage was assessed with established assessment tools. The Manual Muscle Test assessed the muscle performance for 8 muscle groups (MMT-8). Results A total of 11 patients administered with telitacicept (160 mg per week) were included in this study. Post-treatment assessments revealed improvements in all patients according to ACR/EULAR criteria. Notably, there was a significant reduction in the prednisone dosage from baseline to last visit (27.05 ± 12.47 mg to 12.05 ± 7.32 mg; p< 0.005). Enhancements were observed in MMT-8 scores improved (from 109.18 ± 14.18–137.64 ± 15.28; p< 0.005) and in the reduction of creatine kinase (CK) levels (from 2670.27 ± 2675.00 U/l to 561.09 ± 754.09; p< 0.05). Conclusion Telitacicept demonstrated effectiveness in treating refractory inflammatory myopathy, contributing to a significant reduction in steroid dosage among the patients. These findings highlight the potential of telitacicept as a valuable therapeutic option in the management of IIM.

中文翻译：

---

难治性特发性炎性肌病的泰利西普附加治疗：来自一项初步研究的见解


目的 本研究旨在评价基于常规治疗的泰利西普对成人特发性炎症性肌病 （IIM） 的治疗效果，重点关注其对临床表现的影响。方法 纳入 2023 年 1 月至 2024 年 1 月在常规治疗基础上接受泰利西普治疗至少 3 个月的 IIM 患者。对泰利西普的临床反应是根据 ACR/EULAR 总改善评分 （TIS） 的最小、中度和主要改善标准确定的。使用核心集测量 （CSM） 监测疾病活动，而使用既定评估工具评估肌炎损害。手动肌肉测试评估了 8 个肌肉群 （MMT-8） 的肌肉性能。结果 本研究共纳入 11 例接受泰利西普 （每周 160 mg） 的患者。根据 ACR/EULAR 标准，治疗后评估显示所有患者都有所改善。值得注意的是，从基线到最后一次就诊，泼尼松剂量显着减少 （27.05 ± 12.47 mg 至 12.05 ± 7.32 mg;p< 0.005）。观察到 MMT-8 评分提高（从 109.18 ± 14.18-137.64 ± 15.28;p< 0.005）和肌酸激酶 （CK） 水平降低（从 2670.27 ± 2675.00 U/l 降至 561.09 ± 754.09;p< 0.05）。结论 Telitacicept 在治疗难治性炎症性肌病方面显示出有效性，有助于显着减少患者类固醇剂量。这些发现强调了泰利西普作为 IIM 管理中有价值的治疗选择的潜力。